Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $29.73, denoting a +0.61% change from the preceding trading day.

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...

After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...

In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $29.10 ... estimates have a direct correlation with impending stock price performance. To take advantage of this, we've ...

In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $29.10 ... that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of ...

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...